Results 91 to 100 of about 3,861 (173)

Biomechanical Properties of Bones from Rats Treated with Sevelamer [PDF]

, 2011
Sevelamer hydrochloride is used for ten years in patients on dialysis as a phosphate binder.We have previously shown that oral application of sevelamer prevents the bone loss and increases the bone volume in ovariectomized rats1.
Tikvica, Ana, Drača, Natasa, Brnčić, Mladen, Vukičević, Slobodan, Eljuga, Domagoj, Semenski, Damir   +5 more
core   +1 more source

Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia

, 2003
Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.BackgroundIn chronic renal failure (CRF), hyperphosphatemia and an elevated calcium-phosphate product are associated with vascular calcification ...
E. Slatopolsky, J. Finch, A. S. Dusso, S. K. Burke, M. E. Staniforth, H. Liapis, M. Cozzolino   +6 more
core   +1 more source

Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: A two-year follow-up study

, 2007
Sevelamer hydrochloride (HCl) contains multiple amines that may cause a significant dietary acid load. To evaluate the impact of sevelamer on arterial blood gases, we followed two groups of stable hemodialysis patients for 24 months. The Sevelamer Group (
Vlahakos, Demetrios V., Kalogeropoulou, Sofia, Retsa, Kalliopi, Agroyannis, Basil, Bacharaki, Dimitra, Katsoudas, Spiros   +5 more
core   +1 more source

The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil in patients after renal transplantation

, 2007
Titelblatt und Inhaltsverzeichnis Einleitung Material und Methoden Ergebnisse Diskussion LiteraturverzeichnisWechselwirkungen zwischen Arzneimitteln können zu Veränderungen ihrer Blutspiegel führen.
Buhle, Franziska
core   +1 more source

Effects of sevelamer carbonate in patients with ckd and proteinuria. the answer randomized trial

, 2019
Rationale & Objective: Hyperphosphatemia is associated with increased risk for chronic kidney disease (CKD) progression and reduced antiproteinuric effects of renin-angiotensin system (RAS) blockers.
Zoccali C., Ruggiero B., Rubis N., Boccardo P., Peracchi S., Mazzaferro S., Panuccio V., Perna A., Fassino V., Trillini M., Rotondi S., Aparicio C., Cozzolino M., Tartaglione L., Peraro F., Prandini S., Perico N., Diadei O., Carrara F., Celeste A., Bellasi A., Villa D., Ruggenenti P., Kohan D. E., Cugini D., Remuzzi G., Gaspari F., Martinetti D., Giuliano G. A., Mallamaci F., Caridi G., Lecchi V., Stucchi N., Cannata A., Tripepi R., Gherardi G., Carminati S., Perticucci E., Parlongo G., Ferrari S.   +39 more
core   +1 more source

Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?

, 2019
International audienceBackgroundHyperphosphatemia control is a major issue in hemodialysis patients. Both sevelamer and nicotinamide are prescribed for this purpose.
Drueke, Tilman B., Gomila, Cathy, Liabeuf, Sophie, Massy, Ziad A., Lenglet, Aurelie, Alvarez, Jean Claude, Fabresse, Nicolas, Kamel, Saïd, Taupin, Meline   +8 more
core   +1 more source

Hemodiyaliz Hastalarında Sevelamer Vasküler Sertliği Düzeltmekte ve Serum Ürik Asit Düzeyini Azaltmaktadır

Amaç: Sevelamer, pleotropik etkisi ile prebiyotik olarak etki gösterebilir. Bu çalışmanın amacı sevelamerin ürik asit, HbA1c, lipid profili ve arteryel sertlik progresyonu üzerine etkisinin gösterilmesidir.
Demirci, Bahar Gürlek, Bal, Zeynep, Tutal, Emre, Sezer, Siren, Erkmen, Mehtap, Akdogan, Mehtap   +5 more
core   +1 more source

Sevelamer carbonate crystal associated colitis in a hemodialysis patient: a case report. [PDF]

Oxf Med Case Reports
Bseiso O, Qawasmeh M, Zahdeh A, Isayed O, Omari A, Natsheh M.   +5 more
europepmc   +1 more source

Efficacy and safety of ferric citrate tablets in Chinese patients with hyperphosphatemia undergoing maintenance hemodialysis: a multicenter, randomized, open-label, active-controlled, phase III trial. [PDF]

Ren Fail
Ma J, Liu B, Pang J, Wang P, Li Y, Wang C, Zheng D, Wang X, Hu X, Zhao J, Zhang X, Cao C, Wang Z, Xing L, Li S, Cheng H, Huang J, Yang Y, Chen X, Ye K, Yan T, Chen L, Zhang G, Zheng F, Teng S, Zhu Q, Liu H, Li X.   +27 more
europepmc   +1 more source

Clinical Evaluation of Low-Dose Magnesium Carbonate as a Phosphate Binder in Chronic Hemodialysis Patients. [PDF]

Life (Basel)
Tzekov V, Kostadinova T, Artinyan E, Stoyanova R, Valcheva E, Dimov N.   +5 more
europepmc   +1 more source